All In Biotech

Drug Trial Radar · NCT07378865

Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants

A Phase 1, Open-label, Single-dose Study Evaluating the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Subjects

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Feb 13, 2026

Primary completion

Aug 17, 2026

Study completion Aug 17, 2026

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Jan 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ) and its active metabolite in breast milk of lactating female participants. In addition, the purpose is also to evaluate the relative infant dose (RID), safety and tolerability of SUZ and its active metabolite in lactating female participants.

Conditions

  • Pain

Interventions

  • SuzetrigineDrug

    Tablets for Oral Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Amount of SUZ in Breast Milk of Lactating Female ParticipantsTime frame: From Day 1 up to Day 10
  2. Total Amount of SUZ Metabolite in Breast Milk of Lactating Female ParticipantsTime frame: From Day 1 up to Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON - Utah - Salt Lake City Office

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.